Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippi applies for you, and finds you a job.
Masimo's peak revenue was $2.1B in 2024. The peak quarterly revenue was $617.0M in 2022(q4).
Masimo's revenue increased from $224.3m in 2006 to $2.1B currently. That's a 833.59% change in annual revenue.
| Fiscal year / year | Masimo revenue |
|---|---|
| 2009 | $307.1M |
| 2010 | $349.1M |
| 2011 | $439.0M |
| 2012 | $493.2M |
| 2013 | $493.2M |
| 2014 | $586.6M |
| 2015 | $630.1M |
| 2016 | $712.9M |
| 2017 | $790.2M |
| 2018 | $858.3M |
| 2019 | $937.8M |
| 2020 | $1.1B |
| 2021 | $1.2B |
| 2022 | $2.0B |
| 2023 | $2.0B |
| 2024 | $2.1B |
How accurately did Masimo's revenue projections match actual performance?
Masimo saw the greatest revenue growth in 2022, when revenue increased by 64.28%.
Masimo had the lowest revenue growth in 2009, when revenue changed by 0.0%.
| Year | Masimo growth |
|---|---|
| 2009 | 0%↓ |
| 2010 | 14%↑ |
| 2011 | 26%↑ |
| 2012 | 12%↑ |
| 2013 | 0%↓ |
| 2014 | 19%↑ |
| 2015 | 7%↑ |
| 2016 | 13%↑ |
| 2017 | 11%↑ |
| 2018 | 9%↑ |
| 2019 | 9%↑ |
| 2020 | 22%↑ |
| 2021 | 8%↑ |
| 2022 | 64%↑ |
| 2023 | 1%↑ |
| 2024 | 2%↑ |
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2020 | $269.6M | $301.0M | $278.1M | $295.0M |
| 2021 | $299.0M | $305.1M | $307.4M | $327.6M |
| 2022 | $304.2M | $565.3M | $549.3M | $617.0M |
| 2023 | $565.0M | $455.3M | $478.9M | $548.9M |
| 2024 | $492.8M | $496.3M | - | - |
Do you work at Masimo?
Did Masimo meet its revenue projections?
| CEO | Joe E. Kiani |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 6,200 |
| Date Founded | 1989 |
| Headquarters | Irvine, California |
| Number of Locations | 27 |
| Revenue | $2.1B |
| Net Income | $143,500,000 |
| Gross Proft | $1.0B (2024) |
| PE Ratio | -19.71 |
| Tax Rate | 0.0% |
| Market Capitalization | $6.0B |
| Total Assets | $3,210,600,000 |
| Ticker | MASI |
Masimo received early financing of $5.0M on 2016-11-11.
| Series | Round size | Date |
|---|---|---|
| Grant | $5.0M | 11/2016 |
| Investors | Security type |
|---|---|
| Bill & Melinda Gates Foundation | Grant |
Masimo's top competitor, Gilead Sciences, earned an annual revenue of $28.8B.
Masimo's smallest competitor is Protocall Services, Inc. with revenue of $770.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Varian Medical Systems | $104,569 | $3.2B | 10,000 | 2 |
| Thoratec Corporation | $83,629 | $477.6M | 1,048 | - |
| CoolSculpting | $73,648 | $342.1M | 686 | - |
| Seagen | $85,008 | $2.0B | 900 | - |
| Stryker | $69,470 | $22.6B | 43,000 | 2,286 |
| Cepheid | $86,295 | $531.1M | 6,000 | 5 |
| Intersect ENT | $67,446 | $106.7M | 393 | - |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 692 |
| WebMD | $93,501 | $705.0M | 1,800 | 107 |
| Smiths Medical - Wallace | $47,550 | $409.4M | 1,125 | - |
Zippia gives an in-depth look into the details of Masimo, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Masimo. The employee data is based on information from people who have self-reported their past or current employments at Masimo. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Masimo. The data presented on this page does not represent the view of Masimo and its employees or that of Zippia.
Masimo may also be known as or be related to MASIMO CORP, Masimo and Masimo Corporation.